Trastuzumab deruxtecan vs T-DM1 in HER2+mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03
Seock-Ah Im,Binghe Xu,Sung-Bae Kim,Wei-Pang Chung,Yeon Hee Park,Min-Hwan Kim,Ling-Ming Tseng,Chi-Feng Chung,Chiun-Sheng Huang,Jee Hyun Kim,Joanne Wing Yan Chiu,Toshinari Yamashita,Wei Li,Caleb Lee,Soichiro Nishijima,Kyohei Hamada,Yuji Nishiyama,Masahiro Sugihara,Javier Cortes,Hiroji Iwata ANNALS OF ONCOLOGY（2022）
AI 理解论文
溯源树
样例
